Global Small Molecule Multi-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Small Molecule Multi-target Angiogenesis Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor include Chia Tai Tianqing, Teva, Jiangsu Hengrui Pharmaceuticals, TWi Pharmaceuticals, Sanofi, Pfizer, Novartis, Janssen Biotech and Exelixis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Small Molecule Multi-target Angiogenesis Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Small Molecule Multi-target Angiogenesis Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Small Molecule Multi-target Angiogenesis Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Small Molecule Multi-target Angiogenesis Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Small Molecule Multi-target Angiogenesis Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Small Molecule Multi-target Angiogenesis Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Company

Chia Tai Tianqing
Teva
Jiangsu Hengrui Pharmaceuticals
TWi Pharmaceuticals
Sanofi
Pfizer
Novartis
Janssen Biotech
Exelixis
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca.
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

Apatinib
Axitinib
Anlotinib
Vandetanib
Cabozantinib
Lenvatinib
Pazopanib
Sunitinib
Sorafenib
Other
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

Cancer Therapy
Inflammatory and Autoimmune Diseases
Ophthalmic Diseases
Other
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Multi-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Multi-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Multi-target Angiogenesis Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Small Molecule Multi-target Angiogenesis Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecule Multi-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size, 2020 VS 2024 VS 2031
1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Estimates and Forecasts (2020-2031)
1.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Dynamics
2.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
2.2 Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers
2.3 Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges
2.4 Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints
3 Small Molecule Multi-target Angiogenesis Inhibitor Market by Manufacturers
3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Manufacturers (2020-2025)
3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Manufacturers (2020-2025)
3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Sales Price by Manufacturers (2020-2025)
3.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers, Product Type & Application
3.7 Global Small Molecule Multi-target Angiogenesis Inhibitor Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue in 2024
3.8.3 2024 Small Molecule Multi-target Angiogenesis Inhibitor Tier 1, Tier 2, and Tier 3
4 Small Molecule Multi-target Angiogenesis Inhibitor Market by Type
4.1 Small Molecule Multi-target Angiogenesis Inhibitor Type Introduction
4.1.1 Apatinib
4.1.2 Axitinib
4.1.3 Anlotinib
4.1.4 Vandetanib
4.1.5 Cabozantinib
4.1.6 Lenvatinib
4.1.7 Pazopanib
4.1.8 Sunitinib
4.1.9 Sorafenib
4.1.10 Other
4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type
4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2020-2031)
4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2020-2031)
4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type
4.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2020-2031)
4.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2020-2031)
5 Small Molecule Multi-target Angiogenesis Inhibitor Market by Application
5.1 Small Molecule Multi-target Angiogenesis Inhibitor Application Introduction
5.1.1 Cancer Therapy
5.1.2 Inflammatory and Autoimmune Diseases
5.1.3 Ophthalmic Diseases
5.1.4 Other
5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application
5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2020-2031)
5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2020-2031)
5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application
5.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2020-2031)
5.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2020-2031)
6 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region
6.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2020-2031)
6.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2020-2025)
6.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region
7.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region
7.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2020-2025)
7.1.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region (2026-2031)
7.1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2020-2031)
7.2.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2020-2031)
7.3.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2020-2031)
7.4.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Chia Tai Tianqing
8.1.1 Chia Tai Tianqing Comapny Information
8.1.2 Chia Tai Tianqing Business Overview
8.1.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.1.5 Chia Tai Tianqing Recent Developments
8.2 Teva
8.2.1 Teva Comapny Information
8.2.2 Teva Business Overview
8.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.2.5 Teva Recent Developments
8.3 Jiangsu Hengrui Pharmaceuticals
8.3.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
8.3.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
8.4 TWi Pharmaceuticals
8.4.1 TWi Pharmaceuticals Comapny Information
8.4.2 TWi Pharmaceuticals Business Overview
8.4.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.4.5 TWi Pharmaceuticals Recent Developments
8.5 Sanofi
8.5.1 Sanofi Comapny Information
8.5.2 Sanofi Business Overview
8.5.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.5.5 Sanofi Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novartis
8.7.1 Novartis Comapny Information
8.7.2 Novartis Business Overview
8.7.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.7.5 Novartis Recent Developments
8.8 Janssen Biotech
8.8.1 Janssen Biotech Comapny Information
8.8.2 Janssen Biotech Business Overview
8.8.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.8.5 Janssen Biotech Recent Developments
8.9 Exelixis
8.9.1 Exelixis Comapny Information
8.9.2 Exelixis Business Overview
8.9.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.9.5 Exelixis Recent Developments
8.10 Eisai
8.10.1 Eisai Comapny Information
8.10.2 Eisai Business Overview
8.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.10.5 Eisai Recent Developments
8.11 Boehringer Ingelheim
8.11.1 Boehringer Ingelheim Comapny Information
8.11.2 Boehringer Ingelheim Business Overview
8.11.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.11.5 Boehringer Ingelheim Recent Developments
8.12 Bayer
8.12.1 Bayer Comapny Information
8.12.2 Bayer Business Overview
8.12.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.12.5 Bayer Recent Developments
8.13 AstraZeneca.
8.13.1 AstraZeneca. Comapny Information
8.13.2 AstraZeneca. Business Overview
8.13.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
8.13.5 AstraZeneca. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Analysis
9.1.1 Small Molecule Multi-target Angiogenesis Inhibitor Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process
9.2 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
9.2.3 Small Molecule Multi-target Angiogenesis Inhibitor Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings